Long-term dual antiplatelet therapy: pharmacological and clinical implications

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Patients with acute coronary syndrome face a significant risk of recurrent cardiovascular events.
• Dual antiplatelet therapy (DAPT) is standard for preventing atherothrombotic complications post-myocardial infarction.
• Current guidelines recommend at least 12 months of DAPT for acute events.

Purpose of the Study:

• To review the pharmacological properties of antiplatelet agents.
• To evaluate the clinical application of DAPT, particularly long-term use.
• To discuss personalized DAPT strategies balancing ischemic and bleeding risks.

Main Methods:

• Literature review of pharmacological characteristics of antiplatelet agents.
• Analysis of clinical trial data on DAPT duration and outcomes.
• Synthesis of current guidelines and expert recommendations.

Main Results:

• Long-term DAPT (over 12 months) shows potential for better outcomes in high-risk patients.
• Individualized patient assessment is crucial for optimizing DAPT duration.
• Balancing residual ischemic risk against bleeding risk is a key challenge.

Conclusions:

• Long-term DAPT may be beneficial for select high-risk patients.
• Personalized treatment strategies are essential for effective DAPT management.
• Further research is needed to refine DAPT duration guidelines.